A5006084567- Asthma and respiratory diseases
- Renal and related cancers
- Musculoskeletal Disorders and Rehabilitation
- Delphi Technique in Research
- Congenital heart defects research
- Research in Social Sciences
- Allergic Rhinitis and Sensitization
- Orthopedic Infections and Treatments
- Respiratory and Cough-Related Research
- Neurogenetic and Muscular Disorders Research
- Wnt/β-catenin signaling in development and cancer
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Hip disorders and treatments
- Inhalation and Respiratory Drug Delivery
Helsinki University Hospital
2023-2024
University of Helsinki
2010-2024
Kanta-Hämeen Keskussairaala
2013
BackgroundThe combination of an inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) (ICS/LABA) has shown superiority in improving lung function (FEV1) compared with ICS alone. The clinical effect a ICS/LABA depends on the fine-particle fraction pulmonary deposition.ObjectiveWe sought to compare efficacy 2 combinations LABA, namely, fluticasone propionate (FP) formoterol (FORM) (FP/FORM) furoate (FF) vilanterol (VI) (FF/VI), asthmatic adolescents chronic bronchial...
<b>Background:</b> The formulation and particle size of the inhaled medication as well inhaler characteristics affect pulmonary deposition. <b>Aim:</b> To compare efficacy two inhalers with corticosteroid long-acting beta-agonist (ICS/LABA) in asthmatic adolescents chronic bronchial obstruction. <b>Methods:</b> 44 asthmatics aged 12-17 years (median 14y, male 59%) need regular anti-asthmatic for at least 3 months FEV1/FVC <-1,65SD started fluticasone propionate/formoterol (FP/FORM)...